999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada
https://www.rakovinatherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees:
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Jeffrey A. Bacha B.Sc., M.B.A. | Executive Chairman | 120k | N/A | 1968 |
Dr. Mads Daugaard | President, CEO & Chief Scientific Officer | N/A | N/A | N/A |
Mr. David Hyman CA, CBV | CFO & Corporate Secretary | 120k | N/A | 1973 |
Dr. John Langlands Ph.D. | Chief Operating Officer | N/A | N/A | N/A |
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.
Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.